Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 161

1.

Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma.

Lucca LE, Hafler DA.

Immunol Rev. 2017 Mar;276(1):9-25. doi: 10.1111/imr.12529. Review.

PMID:
28258696
2.
3.

MicroRNA profiling of low-grade glial and glioneuronal tumors shows an independent role for cluster 14q32.31 member miR-487b.

Ames HM, Yuan M, Vizcaíno MA, Yu W, Rodriguez FJ.

Mod Pathol. 2017 Feb;30(2):204-216. doi: 10.1038/modpathol.2016.177. Epub 2016 Oct 14.

PMID:
27739438
4.
5.

Ablation of miR-10b Suppresses Oncogene-Induced Mammary Tumorigenesis and Metastasis and Reactivates Tumor-Suppressive Pathways.

Kim J, Siverly AN, Chen D, Wang M, Yuan Y, Wang Y, Lee H, Zhang J, Muller WJ, Liang H, Gan B, Yang X, Sun Y, You MJ, Ma L.

Cancer Res. 2016 Nov 1;76(21):6424-6435. Epub 2016 Aug 28.

PMID:
27569213
6.

The Antitumor Effect of Metformin Is Mediated by miR-26a in Breast Cancer.

Cabello P, Pineda B, Tormo E, Lluch A, Eroles P.

Int J Mol Sci. 2016 Aug 10;17(8). pii: E1298. doi: 10.3390/ijms17081298.

7.

MicroRNA-26a inhibits osteosarcoma cell proliferation by targeting IGF-1.

Tan X, Fan S, Wu W, Zhang Y.

Bone Res. 2015 Dec 22;3:15033. doi: 10.1038/boneres.2015.33. eCollection 2015 Dec 22.

8.

Loss of MYC and E-box3 binding contributes to defective MYC-mediated transcriptional suppression of human MC-let-7a-1~let-7d in glioblastoma.

Wang Z, Lin S, Zhang J, Xu Z, Xiang Y, Yao H, Ge L, Xie D, Kung HF, Lu G, Poon WS, Liu Q, Lin MC.

Oncotarget. 2016 Aug 30;7(35):56266-56278. doi: 10.18632/oncotarget.10517.

9.

Circulating Plasma microRNAs can differentiate Human Sepsis and Systemic Inflammatory Response Syndrome (SIRS).

Caserta S, Kern F, Cohen J, Drage S, Newbury SF, Llewelyn MJ.

Sci Rep. 2016 Jun 20;6:28006. doi: 10.1038/srep28006.

10.

MicroRNAs in glioblastoma multiforme pathogenesis and therapeutics.

Shea A, Harish V, Afzal Z, Chijioke J, Kedir H, Dusmatova S, Roy A, Ramalinga M, Harris B, Blancato J, Verma M, Kumar D.

Cancer Med. 2016 Aug;5(8):1917-46. doi: 10.1002/cam4.775. Epub 2016 Jun 10. Review.

11.

TET3 inhibits TGF-β1-induced epithelial-mesenchymal transition by demethylating miR-30d precursor gene in ovarian cancer cells.

Ye Z, Li J, Han X, Hou H, Chen H, Zheng X, Lu J, Wang L, Chen W, Li X, Zhao L.

J Exp Clin Cancer Res. 2016 May 4;35:72. doi: 10.1186/s13046-016-0350-y.

12.

Utility of Serum miR-125b as a Diagnostic and Prognostic Indicator and Its Alliance with a Panel of Tumor Suppressor Genes in Epithelial Ovarian Cancer.

Zuberi M, Khan I, Mir R, Gandhi G, Ray PC, Saxena A.

PLoS One. 2016 Apr 19;11(4):e0153902. doi: 10.1371/journal.pone.0153902. eCollection 2016 Apr 19.

13.
14.

Twist1-related miR-26b-5p suppresses epithelial-mesenchymal transition, migration and invasion by targeting SMAD1 in hepatocellular carcinoma.

Wang Y, Sun B, Zhao X, Zhao N, Sun R, Zhu D, Zhang Y, Li Y, Gu Q, Dong X, Wang M, An J.

Oncotarget. 2016 Apr 26;7(17):24383-401. doi: 10.18632/oncotarget.8328.

15.

Hypoxia-regulated gene expression explains differences between melanoma cell line-derived xenografts and patient-derived xenografts.

Bhadury J, Einarsdottir BO, Podraza A, Bagge RO, Stierner U, Ny L, Dávila López M, Nilsson JA.

Oncotarget. 2016 Apr 26;7(17):23801-11. doi: 10.18632/oncotarget.8181.

16.

MiR-26a and miR-144 inhibit proliferation and metastasis of esophageal squamous cell cancer by inhibiting cyclooxygenase-2.

Shao Y, Li P, Zhu ST, Yue JP, Ji XJ, Ma D, Wang L, Wang YJ, Zong Y, Wu YD, Zhang ST.

Oncotarget. 2016 Mar 22;7(12):15173-86. doi: 10.18632/oncotarget.7908.

17.

Polymorphisms in pre-miRNA genes and cooking oil fume exposure as well as their interaction on the risk of lung cancer in a Chinese nonsmoking female population.

Yin Z, Li H, Cui Z, Ren Y, Li X, Wu W, Guan P, Qian B, Rothman N, Lan Q, Zhou B.

Onco Targets Ther. 2016 Jan 19;9:395-401. doi: 10.2147/OTT.S96870. eCollection 2016 Jan 19.

18.

Identification of MLL-fusion/MYC⊣miR-26⊣TET1 signaling circuit in MLL-rearranged leukemia.

Huang H, Jiang X, Wang J, Li Y, Song CX, Chen P, Li S, Gurbuxani S, Arnovitz S, Wang Y, Weng H, Neilly MB, He C, Li Z, Chen J.

Cancer Lett. 2016 Mar 28;372(2):157-65. doi: 10.1016/j.canlet.2015.12.032. Epub 2016 Jan 11.

19.

Interplay Between Metabolism and Oncogenic Process: Role of microRNAs.

Arora A, Singh S, Bhatt AN, Pandey S, Sandhir R, Dwarakanath BS.

Transl Oncogenomics. 2015 Dec 29;7:11-27. doi: 10.4137/TOG.S29652. eCollection 2015 Dec 29. Review.

20.

MicroRNA-26a suppresses epithelial-mesenchymal transition in human hepatocellular carcinoma by repressing enhancer of zeste homolog 2.

Ma DN, Chai ZT, Zhu XD, Zhang N, Zhan DH, Ye BG, Wang CH, Qin CD, Zhao YM, Zhu WP, Cao MQ, Gao DM, Sun HC, Tang ZY.

J Hematol Oncol. 2016 Jan 6;9:1. doi: 10.1186/s13045-015-0229-y.

Supplemental Content

Support Center